UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)															
1. Name and Address of Reporting Person *- WIKLER MATTHEW				2. Issuer Name and Ticker or Trading Symbol Matinas BioPharma Holdings, Inc. [MTNB]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director							
(Last) (First) (Middle) C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302				3. Date of Earliest Transaction (Month/Day/Year) 03/31/2019					Office	er (give title belo	ow)	Other (spec	fy belo	w)			
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person									
BEDMINSTER, NJ 07921 (City) (State) (Zip)				Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	any	eemed tion Date, i	3. T	3. Transaction Code (Instr. 8)				quired of (D)	5. Amour Beneficia Reported	nt of Securities ally Owned Following I Transaction(s)		6. Ownersh Form:	ip of Bo	7. Nature of Indirect Beneficial	
				(Month/Day/Ye			Code	V	Amour	(A) or (D)	Price	(Instr. 3 a	nd 4)		\ /		Ownership (Instr. 4)
Common	Stock		03/31/2019				A		14,565 (1)	5 A	\$ 0	111,221			D		
			Table II -				1 cquire	the fo	rm dis	splays a of, or Bei	curre neficia	ently valid	OMB con	spond unle trol numbe			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Ye	3A. Deemed Execution Date (Year) any	4. Transaction Code Year) (Instr. 8)		5.				cisable 7 nn Date A Year) U S (4	7. 7 Am Un Sec (In: 4)	Fitle and count of derlying curities str. 3 and	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Own Form Deriv Secu Direct or In	vative rity: et (D) direct	Beneficia Ownershi (Instr. 4)
					Code V	(A)		Date Exercisa		Expiration Date	Tit	Number of Shares					
Repor	ting O	wners															

	Relationships					
Reporting Owner Name / Address		10% Owner	Officer	Other		
WIKLER MATTHEW C/O MATINAS BIOPHARMA HOLDINGS, INC. 1545 ROUTE 206 SOUTH, SUITE 302 BEDMINSTER, NJ 07921	X					

Signatures

/s/ Jerome D. Jabbour, attorney-in fact for Matthew Wikler	04/03/2019		
**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On March 31, 2019, the Reporting Person was issued 14,565 shares of common stock par value \$.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.